Evidence map›Paper›PMID 35596772›Full record

ArticleJournal of cancer research and clinical oncology2022

Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases.

Robert Damm, Maciej Pech, Paola Cavalli, Florian Haag, Severin Gylstorff, Jazan Omari, Maximilian Thormann, Ricarda Seidensticker, Jens Ricke, Max Seidensticker and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Robert DammDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Maciej PechDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Paola CavalliDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Florian HaagDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Severin GylstorffDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Jazan OmariDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Maximilian ThormannDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany.
Ricarda SeidenstickerDepartment of Radiology, Ludwig-Maximilians-University, Munich, Germany.
Jens RickeDepartment of Radiology, Ludwig-Maximilians-University, Munich, Germany.
Max SeidenstickerDepartment of Radiology, Ludwig-Maximilians-University, Munich, Germany.
Borna ReljaDepartment of Radiology and Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany. info@bornarelja.com.ORCID http://orcid.org/0000-0002-5625-8823
Otto-von-Guericke-Universität Magdeburg · DELudwig-Maximilians-Universität München · DEStädtisches Klinikum Dessau · DE

Funding

Bundesministerium für Bildung und Forschung 13GW0473A
6 · The paper itself

Abstract

backgroundLocoregional therapies, as imaging-guided tumor-directed procedures, are emerging treatment strategies in the management of primary and secondary liver malignancies such as e.g. colorectal cancer liver metastases. As one of those, irradiation-based interstitial high dose rate brachytherapy (iBT) of liver metastases bears a risk of developing focal radiation-induced liver injury (fRILI). Since little is known about biological factors involved in hepatic dysfunction after irradiation, the aim of this study was to identify factors, that may play a role in the underlying mechanism of fRILI, and that potentially may serve as biomarkers for post-therapeutic fRILI to improve specific management and treatment of patients.

methodsTwenty-two patients with hepatic malignancies (tumor patients, TP) underwent iBT with total ablative doses of radiation to the target volume ranging from e.g. 15 to 25 Gy. Hepatobiliary magnetic resonance imaging (MRI) was performed 6 weeks after iBT to quanitify fRILI. Blood samples were taken before (pre) and 6 weeks after (post) iBT from TP, and from ten healthy volunteers (HV controls) for the analyses of humoral mediators: monocyte chemoattractant protein-1 (MCP-1), chemokine (C-X3-C motif) ligand 1 (CX3CL1), vascular endothelial growth factor (VEGF) and beta-nerve growth factor (beta-NGF) using the Multi-Analyte Flow Assay via flow cytometry. Correlation analyses between the humoral mediators (pre and post iBT) with the tumor volume and fRILI were performed.

resultsWhile MCP-1 and CX3CL1 tended to decrease in TP vs. HV, VEGF was significantly decreased in TP vs. HV pre and post iBT (p < 0.05). Beta-NGF levels were significantly increased in TP vs. HV pre and post iBT (p < 0.05). Baseline circulating levels of MCP-1, VEGF and beta-NGF have shown significant positive correlations with the hepatic tumor volume (p < 0.05). Circulating levels of humoral mediators before treatment did not correlate with fRILI, while CX3CL1 and VEGF after iBT have shown significant positive correlations with fRILI (p < 0.05).

conclusionTumor volume and threshold dose of irradiation damage correlated positively with MCP-1 and VEGF as well as NGF and CX3CL, respectively. Thus, investigation of biological mediators in blood samples from tumor patients may provide an appropriate tool to predict fRILI after interstitial HDR brachytherapy of liver metastases.

Indexed as

BrachytherapyLiverLiver NeoplasmsRadiation InjuriesChemokinesHumansNerve Growth FactorRadiotherapy DosageVascular Endothelial Growth Factor AChemokinesNerve Growth FactorVascular Endothelial Growth Factor ABiomarkerCX3CL1Liquid biopsyMCP-1NGFVEGF

Identifiers

PMID35596772
PMCPMC9470622
OpenAlexW4281249272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.